白血病人骨髓间充质干细胞是否是恶性细胞?

本研究探索白血病人的骨髓间充质干细胞是否也具有白血病恶变特征。分别分离培养急性早幼粒细胞白血病(APL)及慢性髓系白血病(CML)患者的骨髓间充质干细胞并与正常对照比较其形态、生长曲线、细胞表面标志及是否带有白血病细胞的恶性克隆性的基因异常标志。结果表明:白血病患者的骨髓间充质干细胞在细胞生物学特征方面与正常健康人无任何明显差异,未发现白血病患者的骨髓间充质干细胞带有白血病细胞的恶性克隆性基因改变。结论:来源于白血病患者的骨髓间充质干细胞并无相应白血病细胞的克隆性异常,提示可能作为自体移植的辅助治疗和细胞治疗或基因治疗的可供选择的细胞载体。

Are Leukemic Patient Bone Marrow Mesenchymal Stem Cells Malignant?

The study was aimed to explore whether there are leukemic characteristics in the bone marrow mesenchymal stem cells(BMMSC)from leukemic patients as compared with normal controls. The mesenchymal stem cells from bone marrow of normal volunteers and patients with APL and CML were isolated, then cultured and proliferated in vitro. The morphology, growth curve and cell surface markers of two different sources mesenchymal stem cells were investigated for detecting whether the bone marrow mesenchymal stem cells derived from leukemia patients have the specific abnormal fusion gene of leukemia cells through fluorescent in situ hybridization. The results indicated that there was no significant difference between the mesenchymal stem cells derived from different subjects, the bone marrow mesenchymal stem cells derived from leukemia patients did not have the clonal malignant fusion gene as seen in the leukemia cells. Taken altogether, mesenchymal stem cells derived from leukemia patients had no biological differences as compared with those from normal volunteers, and no malignant clonal abnormality was found. It is concluded that mesenchymal stem cells derived from leukemia patients as an alternative vehicle may be used for assistant of autologous hematopoietic stem cell transplantation or cell therapy and gene therapy.